Advanced Material Development has appointed Dr Anthony Thomson as chief executive of Life Science subsidiary CoM3D
Thomson, who will also advise on IP commercialisation and join AMD's advisory panel, has held numerous roles in the technology, automotive, health, capital markets and University sectors, most recently managing an exit to US giant Qualcomm.
Specifically, he was CBO of Elephants Child Advisory, chief strategy officer at Isansys Lifecare and held senior roles at Qualcomm; University of Auckland; Euronext; ABN AMRO; BNP Paribas; LIFFE and Chesterton.
John Lee, AMD’s chief executive, said: “I have known Anthony several years and have sought his valuable guidance several times in the history of our company – I look forward to his growing involvement in our day to day business and especially in the application of his skills to the development of CoM3D”.
Thomson has an MSc and a PhD from the University of Otago, is a Fellow of the Royal Society of Medicine and currently a non-executive director of several SMEs.
AMD funds and commercialises university-based research in the area of liquid processing of nanomaterials for use in sensors, electronics, composites, photonics, coatings and nano-barcoding.